Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy

Kim, Young Tae; Kim, Sang Wun; Yoon, Bo Sung; Cho, Hye Jin; Nahm, E.; Kim, Sung Hoon; Kim, Jae Hoon

doi:10.1016/j.ygyno.2006.11.014

Cited by 90 publications

(82 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Otherwise, the use of IS without additional ESA treatment could also benefit at least some patients in terms of improved Hb levels and reduction of RBC transfusions as suggested by early studies in patients with gynecological cancers who received chemotherapy [64,65] and a prospective observational study in patients with cancer-and chemotherapy-associated anemia [66].…”

Section: Oncologymentioning

confidence: 99%

“…iron products). Among the 36 published clinical studies [45][46][47][48][49][50][55][56][57][58][59][60]64,65,70,74,[76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91] that are included in the clinical dossier of Venofer, 26 reported at least some details about adverse drug events; 3 of those reported at least possibly related serious adverse events (all nonfatal, Table 2) [51,76,77]. Three reports included only general statements on safety without further details (e.g., no serious adverse reactions were noted) [47,48,64].…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

“…Three reports included only general statements on safety without further details (e.g., no serious adverse reactions were noted) [47,48,64]. Five reports mentioned that no drug-related adverse events or no adverse events at all have been observed in IS-treated patients [45,46,49,52,65]. Two reports did not provide any safety information [84,88].…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

“…Furthermore, reducing RBC transfusions needs [65,106] can potentially reduce costs for providing RBC units, hospitalization and management of complications.…”

Section: Cost-effectivenessmentioning

confidence: 99%

See 3 more Smart Citations

Iron sucrose – characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas

Béguin¹,

Jaspers

2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Section: Oncologymentioning

confidence: 99%

Section: Safety and Tolerabilitymentioning

confidence: 99%

Section: Safety and Tolerabilitymentioning

confidence: 99%

“…Furthermore, reducing RBC transfusions needs [65,106] can potentially reduce costs for providing RBC units, hospitalization and management of complications.…”

Section: Cost-effectivenessmentioning

confidence: 99%

See 2 more Smart Citations

Iron sucrose – characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas

Béguin¹,

Jaspers

2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

“…Позитивний результат ліку-вання, який характеризувався зростанням толе-рантності до фізичного навантаження, поліпшен-ням функціонального стану пацієнтів, був за-реєстрований в усіх 35 хворих через 4,5 міс. Крім того, у цих пацієнтів (як у групі хворих з анемією, так і без неї) при відсутності суттєвого збільшення рівня гемоглобіну зареєстровано суттєве підвищення ФК ХСН і споживання кисню [29].…”

unclassified

The problem of anemia treatment in patients with chronic heart failure.

Іванов¹,

Kolesnуk²,

Kolesnуk³

et al. 2018

Medicni Perspektivi (Medical Perspectives)

View full text Add to dashboard Cite

Risk of Infection Associated With Administration of Intravenous Iron

et al. 2021

View full text Add to dashboard Cite

IMPORTANCEIntravenous iron is recommended by many clinical guidelines based largely on its effectiveness in reducing anemia. However, the association with important safety outcomes, such as infection, remains uncertain. OBJECTIVE To examine the risk of infection associated with intravenous iron compared with oral iron or no iron. DATA SOURCES Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for randomized clinical trials (RCTs) from 1966 to January 31, 2021. Ongoing trials were sought from ClinicalTrials.gov, CENTRAL, and the World Health Organization International Clinical Trials Search Registry Platform. STUDY SELECTION Pairs of reviewers identified RCTs that compared intravenous iron with oral iron or no iron across all patient populations, excluding healthy volunteers. Nonrandomized studies published since January 1, 2007, were also included. A total of 312 full-text articles were assessed for eligibility. DATA EXTRACTION AND SYNTHESIS Data extraction and risk of bias assessments were performed according to the Preferred Reporting Items of Systematic Reviews and Meta-analyses (PRISMA) and Cochrane recommendations, and the quality of evidence was assessed using the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) approach. Two reviewers extracted data independently. A random-effects model was used to synthesize data from RCTs. A narrative synthesis was performed to characterize the reporting of infection. MAIN OUTCOMES AND MEASURESThe primary outcome was risk of infection. Secondary outcomes included mortality, hospital length of stay, and changes in hemoglobin and red blood cell transfusion requirements. Measures of association were reported as risk ratios (RRs) or mean differences.RESULTS A total of 154 RCTs (32 920 participants) were included in the main analysis. Intravenous iron was associated with an increased risk of infection when compared with oral iron or no iron (RR, 1.17; 95% CI, 1.04-1.31; I 2 = 37%; moderate certainty of evidence). Intravenous iron also was associated with an increase in hemoglobin (mean difference, 0.57 g/dL; 95% CI, 0.50-0.64 g/dL; I 2 = 94%) and a reduction in the risk of requiring a red blood cell transfusion (RR, 0.93; 95% CI, 0.76-0.89; I 2 = 15%) when compared with oral iron or no iron. There was no evidence of an effect on mortality or hospital length of stay. (continued) Key Points Question In patients who require treatment with intravenous iron, what is the evidence that this intervention increases the risk of developing a new infection? Findings In this systematic review and meta-analysis of 154 randomized clinical trials that included 32 920 participants, intravenous iron was associated with an increased risk of infection. Meaning The results of this study suggest that, despite broad advocacy in clinical guidelines, intravenous iron may increase the risk of infection, which must be balanced with the potential benefits of treating anemia and reducing blood transfusion requirements.

show abstract

Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy

Cited by 90 publications

References 36 publications

Iron sucrose – characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas

Iron sucrose – characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas

The problem of anemia treatment in patients with chronic heart failure.

Risk of Infection Associated With Administration of Intravenous Iron

Contact Info

Product

Resources

About